ImmunityBio Inc. saw its stock surge by 31.58% as it reached a 52-week high, reflecting strong investor confidence.
The significant catalyst for this movement was the announcement that ImmunityBio's ANKTIVA® achieved preliminary net product revenue of approximately $113 million in 2025, marking a remarkable 700% year-over-year increase. This impressive growth indicates strong market demand and solidifies the company's position in the biopharmaceutical sector. Additionally, the Saudi FDA granted approval for ANKTIVA® in combination with immune checkpoint inhibitors, which is expected to drive further international market expansion.
This revenue growth and regulatory approval not only enhance ImmunityBio's market presence but also position the company favorably for future growth, especially with ongoing clinical trials and strategic expansions planned in the Middle East.
Wall Street analysts forecast IBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBRX is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast IBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBRX is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.150
Low
5.00
Averages
7.33
High
9.00
Current: 6.150
Low
5.00
Averages
7.33
High
9.00
Jefferies
Buy
upgrade
$8 -> $9
2025-12-12
Reason
Jefferies
Price Target
$8 -> $9
AI Analysis
2025-12-12
upgrade
Buy
Reason
Jefferies raised the firm's price target on ImmunityBio to $9 from $8 and keeps a Buy rating on the shares. The firm believes ImmunityBio is in execution mode to continue expanding the company's geographic and commercial presence and to advance the pipeline, and today's EMA conditional marketing authorization recommendation for Anktiva in NMIBC-CIS builds on existing approvals in the U.S. and U.K. The company is continuing regulatory dialogue on the papillary disease and also awaiting NCCN guideline decision and BCG-naive data in the second half of 2026 could be another label expansion opportunity, Jefferies adds.
Piper Sandler
Neutral -> Overweight
upgrade
$5
2025-05-20
Reason
Piper Sandler
Price Target
$5
2025-05-20
upgrade
Neutral -> Overweight
Reason
Piper Sandler upgraded ImmunityBio to Overweight from Neutral with a price target of $5, up from $4.25.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IBRX
Unlock Now
Piper Sandler
Neutral -> Overweight
upgrade
$5
2025-05-20
Reason
Piper Sandler
Price Target
$5
2025-05-20
upgrade
Neutral -> Overweight
Reason
Piper Sandler upgraded ImmunityBio to Overweight from Neutral with a price target of $5, up from $4.25, following a transfer of coverage. The company is developing Anktiva, t-haNK and M-ceNK cell therapies and DNA vaccines to restore the immune system's ability to kill cancer, the analyst tells investors in a research note. The firm says Anktiva is off to a strong launch in non-muscle invasive bladder cancer, with sales forecast of $83.5M in 2025. Piper sees multiple label expansion opportunities despite the refusal to file letter issued by the FDA for Anktiva in non-muscle invasive bladder cancer that is unresponsive to treatment with Bacillus Calmette-Guerin.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$30
2025-04-23
Reason
D. Boral Capital
Jason Kolbert
Price Target
$30
2025-04-23
Maintains
Strong Buy
Reason
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
